Letter from the Editor

 

Dear Reader,



The EADV 2021 was a congress of innovations in inflammatory skin diseases.

In psoriasis, an aryl hydrocarbon receptor agonist and a PDE4 inhibitor showed high efficacy and safety in clinical trials. Deucavacitinib is a TYK2 inhibitor with excellent efficacy and safety. Bimikizumab is an IL-17A and F antibody with superb efficacy and safety.

The treatment of atopic dermatitis has been revolutionised by new biologics and small molecules. The positioning of these innovations in the treatment in real practice is discussed in various presentations.

The innovations in psoriasis and atopic dermatitis are also developing the treatment of vitiligo, hidradenitis chronica suppurativa, and alopecia areata.

Insights into the pathogenesis of these diseases are accompanied by the development of pathogenesis-based treatments.

In inflammatory skin diseases, it is realised that these diseases are multifactorial and that patients may differ from each other by an individual treatment responsiveness and unresponsiveness. Current research is focussing on understanding these differences in terms of biomarkers.

In this report, major treatment innovations are highlighted. The impact of these developments in real-world evidence studies is expected to follow at future congresses.

 

Best Regards,

Peter CM van de Kerkhof

 

Biography

Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was board member of various international societies. Current interests are pathogenesis and development of biomarkers for psoriasis; real clinical practice research; and personalised medicine.

Conflict of Interest Statement:Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma,Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant.Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.



Posted on 18 November 202126 November 2021